Liu Boyan, Du Yanhui, Cong Lixin, Jia Xiaoying, Yang Ge
Department of Geriatrics, Affiliated Hospital, Changchun University of Traditional Chinese Medicine, Changchun 130000, China.
Department of Neurology, Jilin Province People's Hospital, Changchun 130000, China.
Evid Based Complement Alternat Med. 2016;2016:9781715. doi: 10.1155/2016/9781715. Epub 2016 Jun 5.
Danshen was able to reduce the risk of the patients with coronary heart disease (CHD), but the mechanism is still widely unknown. Biochemical indices (lipid profile, markers of renal and liver function, and homocysteine (Hcy)) are closely associated with CHD risk. We aimed to investigate whether the medicine reduces CHD risk by improving these biochemical indices. The patients received 10 Danshen pills (27 mg/pill) in Dashen group, while the control patients received placebo pills, three times daily. The duration of follow-up was three months. The serum biochemical indices were measured, including lipid profiles (LDL cholesterol (LDL-C), HDL-C, total cholesterol (TC), triglycerides (TG), apolipoprotein (Apo) A, ApoB, ApoE, and lipoprotein (a) (Lp(a))); markers of liver function (gamma-glutamyl transpeptidase (GGT), total bilirubin (TBil), indirect bilirubin (IBil), and direct bilirubin (DBil)); marker of renal function (uric acid (UA)) and Hcy. After three-month follow-up, Danshen treatment reduced the levels of TG, TC, LDL-C, Lp(a), GGT, DBil, UA, and Hcy (P < 0.05). In contrast, the treatment increased the levels of HDL-C, ApoA, ApoB, ApoE, TBil, and IBil (P < 0.05). Conclusion. Danshen can reduce the CHD risk by improving the biochemical indices of CHD patients.
丹参能够降低冠心病（CHD）患者的风险，但其机制仍尚不明确。生化指标（血脂谱、肝肾功能标志物及同型半胱氨酸（Hcy））与冠心病风险密切相关。我们旨在研究该药物是否通过改善这些生化指标来降低冠心病风险。丹参组患者每日三次服用10粒丹参滴丸（每粒27毫克），而对照组患者服用安慰剂滴丸。随访期为三个月。检测血清生化指标，包括血脂谱（低密度脂蛋白胆固醇（LDL-C）、高密度脂蛋白胆固醇（HDL-C）、总胆固醇（TC）、甘油三酯（TG）、载脂蛋白（Apo）A、ApoB、ApoE及脂蛋白（a）（Lp(a)））；肝功能标志物（γ-谷氨酰转肽酶（GGT）、总胆红素（TBil）、间接胆红素（IBil）及直接胆红素（DBil））；肾功能标志物（尿酸（UA））及Hcy。经过三个月的随访后，丹参治疗降低了TG、TC、LDL-C、Lp(a)、GGT、DBil、UA及Hcy的水平（P<0.05）。相反，该治疗提高了HDL-C、ApoA、ApoB、ApoE、TBil及IBil的水平（P<×0.05）。结论。丹参可通过改善冠心病患者的生化指标来降低冠心病风险。
